ClinicalTrials.gg
TerminatedNCT00163241Updated Mar 3, 2021

Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression

A Phase 3 interventional study of celecoxib in Osteoarthritis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 130 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Prevention

Why this study was terminated
Please see detailed description for termination reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.

Enrollment
4th of 14
666 · median 150
Started
2004
with 4 others
Phase 3
3 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
4 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 4th largest by enrollment, is one of 5 that started in 2004, is one of 3 in phase 3, and was the 4th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, or all of them as a file.
02

Study summary

Objectives of the study:

Primary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered once daily (QD) for 24 months in slowing disease progression as assessed radiographically in subjects with osteoarthritis (OA) of the hipSecondary:Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered QD for 24 months in treating disease signs and symptoms in subjects with OA of the hip.Evaluate the ability of a continuous 24-month intake of celecoxib 200 mg QD versus placebo to reduce number of subjects eligible for hip replacement according to the investigator.Evaluate the tolerability and safety of a continuous 24-month intake of celecoxib 200 mg QD versus placebo in subjects with OA of the hip.

Read the detailed description

The study was terminated on 19 January 2006, prematurely, as a result of low enrollment Safety concerns did not lead to the decision to terminate this study.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is 50 years of age or older.
  • If the subject is a female and of , or less than 2 years , she must have been using adequate during her last menses and will use adequate contraception during the study, is not lactating, and has had a negative urine pregnancy test within 24 hours prior to receiving the first dose of study medication. Women less than two years post-menopausal are considered of childbearing potential for the purposes of this study.
  • The subject is diagnosed as having OA of the hip as defined by the American College of Rheumatology (ACR) criteria (see Appendix B)
  • The subject has symptomatic OA, as defined by the presence of daily hip pain for at least 1 month (not necessarily continuously) during the 2 months prior to screening visit.
  • The subject has hip pain of > or equal to 3 and \< or equal to 9 on a 10-point Visual Numerical Scale (VNS) in the index hip.
  • Subjects with OA of the knee associated with OA of the hip will be included provided knee OA pain intensity is inferior to hip's one and no knee surgery is expected during the study.
  • Subjects are functional class I, II or III according to the Steinbrocker criteria (see Appendix C).
  • The subject is eligible for pharmacologic treatment to control arthritis symptoms.
  • The subject has provided written before undergoing any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Bilateral hip OA with contralateral hip more severe symptomatically or radiologically than the index hip.
  • The subject has evidence of secondary hip OA.
  • Septic arthritis
  • Systemic or local inflammatory joint disease (e.g. psoriatic arthritis, spondylarthropathy, systemic lupus erythematosus, etc.)
  • Gout
  • Recurrent episode of pseudogout
  • Paget's disease
  • Articular fracture
  • Ochronosis
  • Acromegaly
  • Haemochromatosis
  • Wilson's disease
  • Primary osteochondromatosis
  • Osteonecrosis
  • Slipped Capital Femoral Epiphysis (SCFE)
  • The subject has a concomitant inflammatory rheumatic condition, which may interfere with the assessment of OA, or acute joint trauma at the index hip.
  • The subject has received oral, intramuscular, intravenous, or soft tissue injection of within 4 weeks prior to the screening visit.
  • The subject has received an intra-articular injection of corticosteroids or hyaluronic acid in the index hip within 12 weeks prior to the screening visit.
  • The subject has received diacerein, chondroitin sulfate, glucosamine sulfate, doxycycline or avocado/soybean unsaponifiables within 12 weeks prior to the screening visit.
  • Arthroscopy or a corrective surgery of the index hip has been performed.
  • Arthroscopy or a corrective surgery of the contralateral hip has been performed within the 6 months prior to the screening visit .
  • Total replacement of the contralateral hip joint was performed within 6 months prior to the screening visit.
  • The subject is felt to require hip arthroplasty by the investigator at screening visit.
  • The subject has an active of any type. Subjects who have a history of basal cell carcinoma that has been successfully treated are acceptable. Subjects with a history of other malignancies that have been successfully treated and who have no evidence of recurrence for at least 5 years before study are also acceptable.
  • The subject has been diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to the screening visit.
  • The subject has a history of recurrent ulceration or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any other condition, which in the investigator's opinion might preclude use of NSAIDs.
  • The subject has a history of intolerance to paracetamol, opioids and tramadol such that it is felt that an adequate non-anti-inflammatory rescue analgesic regimen cannot be safely prescribed, or has a history of alcohol or substance abuse.
  • The subject has known to celecoxib, demonstrated allergic-type reactions to sulfonamides, experienced asthma, urticaria or allergic-type reactions after taking sulfonamides, aspirin (acetylsalicylic acid [ASA]), lactose or NSAIDs.
  • The subject has been diagnosed as having or has been treated for gastrointestinal bleeding within 30 days before the screening visit.
  • The subject has previously been admitted to this study.
  • The subject has a likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (see Section 9 "Concomitant therapy").
  • The subject has severe disease, likely to jeopardize the planned completion of the study
  • The subject has abnormal baseline findings and or any other condition, which, in the investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  • The subject is not literate in French nor English or is unable according to the investigator to answer questions.
  • The subject has received any drug within 30 days prior to the screening visit.
  • The subject has a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, , previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.
  • The subject has congestive heart failure (Class II-IV).
  • The subject is using aspirin, including low dose aspirin.
  • The subject is using other antiplatelet agents (ticlopidine, clopidogrel, dipyridamole).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
666 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is the change in the minimal JSW of the index hip during the 24-month follow up, compared to baseline. This endpoint will be expressed as the proportion of subjects achieving a 0.5 mm decrease in JSW on a radiograph and

Secondary outcomes

  1. Number of days with rescue medication usage by drug category: paracetamol /paracetamol combination products, opioid/opioid combination products, celecoxib and other (e.g., propoxyphene) WOMAC subscales: pain and function (in comparison to baseline

07

Study locations

130 sites
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 1L7, Canada
  • Pfizer Investigational Site
    Kitchener, Ontario N2M 5N6, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4V2, Canada
  • Pfizer Investigational Site
    Newmarket, Ontario L3Y 3R7, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Sainte-Foy, Quebec G1V 3M7, Canada
  • Pfizer Investigational Site
    Sainte-foy, Quebec G1V 4G2, Canada
  • Pfizer Investigational Site
    Trois-Revieres, Quebec G8Z 1Y2, Canada
  • Pfizer Investigational Site
    St. John's, A1C 5B8, Canada
  • Pfizer Investigational Site
    Angers, 49100, France
  • Pfizer Investigational Site
    Antibes, 06600, France
  • Pfizer Investigational Site
    Arles, 13200, France
  • Pfizer Investigational Site
    Avignon, 84000, France
  • Pfizer Investigational Site
    Bagnols Sur Ceze, 30200, France
  • Pfizer Investigational Site
    Beauvais, 6000, France
  • Pfizer Investigational Site
    Belfort, 90000, France
  • Pfizer Investigational Site
    Boulogne Sur Mer, 62200, France
  • Pfizer Investigational Site
    Caen, 14000, France
  • Pfizer Investigational Site
    Cahors, 46000, France
  • Pfizer Investigational Site
    Cannes La Boca, 06150, France
  • Pfizer Investigational Site
    Castelnaudary, 11400, France
  • Pfizer Investigational Site
    Chateuauroux, 36000, France
  • Pfizer Investigational Site
    Chaumont, 52100, France
  • Pfizer Investigational Site
    Cherbourg, 50100, France
  • Pfizer Investigational Site
    Clamart, 92140, France
  • Pfizer Investigational Site
    Clichy, 92110, France
  • Pfizer Investigational Site
    Colmar, 68000, France
  • Pfizer Investigational Site
    Corbeil Essonnes, 91100, France
  • Pfizer Investigational Site
    Cornebarrieu, 31700, France
  • Pfizer Investigational Site
    Courbevoie, 92200, France
  • Pfizer Investigational Site
    Creteil, 94000, France
  • Pfizer Investigational Site
    Dax, 40100, France
  • Pfizer Investigational Site
    Digne Les Bains, 04000, France
  • Pfizer Investigational Site
    Dijon, 21000, France
  • Pfizer Investigational Site
    Epernay, 51200, France
  • Pfizer Investigational Site
    Firminy, 42700, France
  • Pfizer Investigational Site
    Fontainebleau, 77300, France
  • Pfizer Investigational Site
    Gardanne, 13120, France
  • Pfizer Investigational Site
    Gonesse, 95500, France
  • Pfizer Investigational Site
    Grenoble, 38000, France
  • Pfizer Investigational Site
    Issy Les Moulineaux, 92130, France
  • Pfizer Investigational Site
    Ivry Sur Seine, 94200, France
  • Pfizer Investigational Site
    Jonzac, 17500, France
  • Pfizer Investigational Site
    Joue Les Tours, 37300, France
  • Pfizer Investigational Site
    L'Aigle, 61300, France
  • Pfizer Investigational Site
    L'union, 31240, France
  • Pfizer Investigational Site
    La Celle Saint Cloud, 78170, France
  • Pfizer Investigational Site
    La Rochelle, 17000, France
  • Pfizer Investigational Site
    Landivisiau, 29400, France
  • Pfizer Investigational Site
    Langon, 33210, France
  • Pfizer Investigational Site
    Laval Cedex, 53015, France
  • Pfizer Investigational Site
    Le Perreus Sur Marne, 94000, France
  • Pfizer Investigational Site
    Les Angles, 30133, France
  • Pfizer Investigational Site
    Libourne Cedex, 333505, France
  • Pfizer Investigational Site
    Limoges, 87042, France
  • Pfizer Investigational Site
    Lisieux, 14100, France
  • Pfizer Investigational Site
    Lunel, 34400, France
  • Pfizer Investigational Site
    Lyon, 69002, France
  • Pfizer Investigational Site
    Lyon, 69003, France
  • Pfizer Investigational Site
    Lyon, 69006, France
  • Pfizer Investigational Site
    Lyon, 69007, France
  • Pfizer Investigational Site
    Maisons Alfort, 94700, France
  • Pfizer Investigational Site
    Marseille Cedex 05, 13354, France
  • Pfizer Investigational Site
    Marseille, 13008, France
  • Pfizer Investigational Site
    Marseille, 13015, France
  • Pfizer Investigational Site
    Martigues, 13500, France
  • Pfizer Investigational Site
    Montgeron, 91230, France
  • Pfizer Investigational Site
    Montigny le Bretonneux, 78180, France
  • Pfizer Investigational Site
    Montlucon, 03100, France
  • Pfizer Investigational Site
    Montpellier, 34070, France
  • Pfizer Investigational Site
    Montpellier, 34100, France
  • Pfizer Investigational Site
    Montpellier, 34295, France
  • Pfizer Investigational Site
    Moulins, 03000, France
  • Pfizer Investigational Site
    Nancy, 54000, France
  • Pfizer Investigational Site
    Nantes, 44000, France
  • Pfizer Investigational Site
    Neufchateau, 88300, France
  • Pfizer Investigational Site
    Nevers, 58000, France
  • Pfizer Investigational Site
    Nice, 06000, France
  • Pfizer Investigational Site
    Nimes, 30900, France
  • Pfizer Investigational Site
    Nogent le Rotrou, 28400, France
  • Pfizer Investigational Site
    Nosel, 77186, France
  • Pfizer Investigational Site
    Obernai, 67210, France
  • Pfizer Investigational Site
    Orleans Cedex 01, 45000, France
  • Pfizer Investigational Site
    Orleans Cedex 01, 45032, France
  • Pfizer Investigational Site
    Orly, 94310, France
  • Pfizer Investigational Site
    Ormesson Sur Marne, 94490, France
  • Pfizer Investigational Site
    Orthez, 64300, France
  • Pfizer Investigational Site
    Paris Cedex 12, 75571, France
  • Pfizer Investigational Site
    Paris, 75011, France
  • Pfizer Investigational Site
    Paris, 75015, France
  • Pfizer Investigational Site
    Paris, 75017, France
  • Pfizer Investigational Site
    Paris, 75018, France
  • Pfizer Investigational Site
    Paris, 75020, France
  • Pfizer Investigational Site
    Petit Quevilly, 76140, France
  • Pfizer Investigational Site
    Poitiers, 86000, France
  • Pfizer Investigational Site
    Puteaux, 92800, France
  • Pfizer Investigational Site
    Quimper, 29000, France
  • Pfizer Investigational Site
    Reims, 51100, France
  • Pfizer Investigational Site
    Rennes, 1584, France
  • Pfizer Investigational Site
    Rennes, 35000, France

Showing the first 100 of 130 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Jun 2004
Completion
Jan 2006
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00163241
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Jun 2004
Completion
Jan 2006
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion